Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial
Authors
Keywords
-
Journal
Therapeutic Innovation & Regulatory Science
Volume 56, Issue 5, Pages 785-794
Publisher
Springer Science and Business Media LLC
Online
2022-06-14
DOI
10.1007/s43441-022-00420-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
- (2022) Adriaan A. Voors et al. NATURE MEDICINE
- Comments on “Sample size formula for a win ratio endpoint” by R. X. Yu and J. Ganju
- (2022) Samvel B. Gasparyan et al. STATISTICS IN MEDICINE
- Win odds: An adaptation of the win ratio to include ties
- (2021) Edgar Brunner et al. STATISTICS IN MEDICINE
- Power and sample size calculation for the win odds test: application to an ordinal endpoint in COVID-19 trials
- (2021) Samvel B. Gasparyan et al. Journal of Biopharmaceutical Statistics
- Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2021) Mikhail N Kosiborod et al. Lancet Diabetes & Endocrinology
- Endpoints for randomized controlled clinical trials for COVID-19 treatments
- (2020) Lori E Dodd et al. Clinical Trials
- Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial
- (2020) Scott R Evans et al. Clinical Trials
- Adjusted win ratio with stratification: Calculation methods and interpretation
- (2020) Samvel B Gasparyan et al. STATISTICAL METHODS IN MEDICAL RESEARCH
- Lack of harmonization of coronavirus disease ordinal scales
- (2020) Deborah A Zarin et al. Clinical Trials
- Effects of da pagliflozin on prevention of major clinical events and recovery in patients with re spiratory failure because of COVID‐ 19 : Design and rationale for the DARE‐19 study
- (2020) Mikhail Kosiborod et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- A weighted combined effect measure for the analysis of a composite time-to-first-event endpoint with components of different clinical relevance
- (2017) Geraldine Rauch et al. STATISTICS IN MEDICINE
- Development and Evolution of a Hierarchical Clinical Composite End Point for the Evaluation of Drugs and Devices for Acute and Chronic Heart Failure
- (2016) Milton Packer CIRCULATION
- Large sample inference for a win ratio analysis of a composite outcome based on prioritized components: Table 1.
- (2015) Ionut Bebu et al. BIOSTATISTICS
- The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities
- (2011) S. J. Pocock et al. EUROPEAN HEART JOURNAL
- Generalized pairwise comparisons of prioritized outcomes in the two-sample problem
- (2010) Marc Buyse STATISTICS IN MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started